Pituitary Cancer Market
Pituitary Cancer Market Size, Share & Industry Analysis, By Type (Prolactinoma, Cushing's Disease, Acromegaly, Non-Functioning Pituitary Adenoma, Others), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Others), By End-User (Hospitals, Specialty Clinics, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) -- Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The global pituitary cancer market is expected to grow at a CAGR of XX% during the forecast period (2024-2031), reaching a market value of USD XX million by 2024 and USD YY million by 2031. North America is projected to be the dominant region in the market. The growth of the pituitary cancer market is driven by the increasing incidence of pituitary tumors, advancements in diagnostic imaging techniques, and the development of targeted therapies.
Pituitary Cancer Market Dynamics
Rising incidence of pituitary tumors and increasing awareness driving market growth The rising global incidence of pituitary tumours is a major trend driving the pituitary cancer market. Pituitary tumours, while mostly benign, can cause severe morbidity and necessitate rapid identification and treatment. The growing knowledge of pituitary problems, as well as the availability of modern diagnostic imaging tools like MRI and CT scans, are allowing for early detection and treatment of pituitary tumours. Educational initiatives by healthcare organisations and patient support groups are helping to raise awareness and diagnose pituitary tumours.
Advancements in targeted therapies and personalized medicine approaches The development of targeted therapeutics and personalised medicine methods is a major driver in the pituitary cancer market. Targeted medicines, such as somatostatin analogues and dopamine agonists, are intended to target specific biochemical processes involved in pituitary tumour growth and hormone production. These medicines have higher efficacy and fewer negative effects than standard chemotherapy. Furthermore, as we gain a better understanding of the genetic and molecular foundation of pituitary tumours, we can design personalised therapy regimens that are suited to the needs of each patient. Precision medicine approaches are projected to improve patient outcomes while also driving growth in the pituitary cancer industry.
High cost of treatment and limited reimbursement policies hindering market growth The high expense of pituitary cancer therapy, particularly sophisticated medicines and surgical procedures, is a significant barrier to market expansion. Pituitary cancer treatment frequently requires a multimodal approach, involving surgery, radiation therapy, and targeted drugs, which can result in significant healthcare costs for patients and healthcare systems. Furthermore, restrictive reimbursement rules and insurance coverage for pituitary cancer treatments in some areas may limit patients' access to sophisticated therapy. The lack of standardised treatment standards, as well as the variable reimbursement landscape between countries, present hurdles for market actors and may have an impact on the uptake of new therapies.
Segment Overview
Non-functioning pituitary adenomas dominate the market, driven by increasing diagnosis rates
Non-functioning pituitary adenomas (NFPAs) dominate the pituitary cancer market. NFPAs are benign tumours that do not produce extra hormones but can cause symptoms because to their size and compression of nearby structures. The growing diagnosis rates of NFPAs, due to enhanced imaging techniques and more awareness, are driving market expansion in this sector. Recent advances in endoscopic endonasal surgery procedures have improved surgical outcomes for NFPAs, making it the recommended treatment method. Furthermore, continuing research into the molecular aetiology of NFPAs is laying the groundwork for the development of targeted medicines and personalised treatment approaches.
Regional Outlook
North America leads the pituitary cancer market, driven by advanced healthcare infrastructure and research
North America dominates the pituitary cancer market, with the biggest revenue share. The region's growth is fuelled by a well-established healthcare infrastructure, widespread use of innovative diagnostic and treatment technologies, and the presence of major pharmaceutical and biotechnology companies. The United States is the primary contributor to the North American market, having a big patient population and high healthcare spending. The region's concentration on R&D, together with favourable reimbursement regulations, contributes to the growth of the pituitary cancer market in North America.
Recent news and statistics demonstrate the region's dominance:
-
According to the American Cancer Society, around 17,000 new instances of pituitary tumours are detected in the US annually.
-
In 2021, the FDA authorised Mycapssa (octreotide) capsules as the first oral somatostatin analogue for long-term maintenance treatment of acromegaly (source: Chiasma, Inc.).
Competitive Intelligence
The pituitary cancer market is dominated by a few major firms and a large number of small and medium-sized businesses. Leading market players include Novartis AG, Pfizer Inc., Ipsen Pharma, Chiasma, Inc., and Crinetics Pharmaceuticals, Inc. These companies are investing in R&D to create novel targeted medicines and improve current treatment choices. Strategic partnerships, mergers, and acquisitions are popular methods used by market participants to improve their product portfolios and geographical reach. The pituitary cancer market has a promising future, thanks to an increase in the incidence of pituitary tumours, advances in diagnostic and treatment technology, and the development of targeted therapeutics.
Analyst Opinion
The pituitary cancer market is predicted to increase steadily in the future years, owing to the rising incidence of pituitary tumours and the development of targeted medicines. The increasing awareness of pituitary problems, as well as the availability of improved diagnostic imaging techniques, will help to diagnose and treat pituitary malignancies early on. The development of personalised treatment techniques based on pituitary tumour molecular profiling will be a key trend influencing the market's future growth. North America, lead by the United States, will continue to dominate the pituitary cancer market, owing to its advanced healthcare infrastructure, research capacity, and favourable reimbursement regulations. However, high treatment costs and restricted reimbursement in certain locations may impede market expansion and patient access to innovative medicines.
Major Players
-
Novartis AG
-
Pfizer Inc.
-
Ipsen Pharma
-
Chiasma, Inc.
-
Crinetics Pharmaceuticals, Inc.
-
Recordati S.p.A.
-
Bristol-Myers Squibb Company
-
Eli Lilly and Company
-
Mylan N.V.
-
Inovio Pharmaceuticals, Inc.
Developments
-
Recordati S.p.A. acquired EUSA Pharma in June 2021, expanding its rare disease portfolio to include the pituitary cancer medication Sylvant (siltuximab).
-
In March 2021, Crinetics Pharmaceuticals, Inc. reported positive topline results from the Phase 1 study of CRN04894, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for the treatment of congenital hyperinsulinism and acromegaly.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)*
5. COMPANY PROFILES
5.1. Novartis AG
5.2. Pfizer Inc.
5.3. Ipsen Pharma
5.4. Chiasma, Inc.
5.5. Crinetics Pharmaceuticals, Inc.
5.6. Recordati S.p.A.
5.7. Bristol-Myers Squibb Company
5.8. Eli Lilly and Company
5.9. Mylan N.V.
5.10. Inovio Pharmaceuticals, Inc.*
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Rising incidence of pituitary tumors and increasing awareness driving market growth
6.1.2. Development of targeted therapies and personalized medicine approaches
6.1.3. Increasing adoption of minimally invasive surgical techniques
6.2. Market Drivers
6.2.1. Advancements in diagnostic imaging techniques enabling early detection
6.2.2. Growing awareness about pituitary disorders and available treatment options
6.2.3. Increasing healthcare expenditure and improving reimbursement policies
6.3. Market Restraints
6.3.1. High cost of treatment and limited reimbursement policies hindering market growth
6.3.2. Lack of standardized treatment guidelines across different regions
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Prolactinoma
7.1.1. Microprolactinoma
7.1.2. Macroprolactinoma
7.2. Cushing's Disease
7.2.1. Adrenocorticotropic hormone (ACTH)-secreting adenomas
7.2.2. Corticotropin-releasing hormone (CRH)-secreting adenomas
7.3. Acromegaly
7.3.1. Growth hormone (GH)-secreting adenomas
7.3.2. Growth hormone-releasing hormone (GHRH)-secreting adenomas
7.4. Non-Functioning Pituitary Adenoma
7.4.1. Gonadotroph adenomas
7.4.2. Null cell adenomas
7.5. Others
7.5.1. Thyrotropin (TSH)-secreting adenomas
7.5.2. Mixed pituitary adenomas
8. BY TREATMENT (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Surgery
8.1.1. Transsphenoidal surgery
8.1.2. Transcranial surgery
8.2. Radiation Therapy
8.2.1. Stereotactic radiosurgery
8.2.2. Fractionated radiotherapy
8.3. Chemotherapy
8.3.1. Temozolomide
8.3.2. Capecitabine
8.4. Targeted Therapy
8.4.1. Somatostatin analogs
8.4.2. Dopamine agonists
8.5. Others
8.5.1. Hormone replacement therapy
8.5.2. Immunotherapy
9. BY END-USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospitals
9.1.1. Inpatient care
9.1.2. Outpatient care
9.2. Specialty Clinics
9.2.1. Endocrinology clinics
9.2.2. Oncology clinics
9.3. Others
9.3.1. Research institutes
9.3.2. Academic medical centers
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Type:
-
Prolactinoma
-
Cushing's Disease
-
Acromegaly
-
Non-Functioning Pituitary Adenoma
-
Others
By Treatment:
-
Surgery
-
Radiation Therapy
-
Chemotherapy
-
Targeted Therapy
-
Others
By End-User:
-
Hospitals
-
Specialty Clinics
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511